Liqing Ni
About
In The Last Decade
Liqing Ni
9 papers receiving 404 citations
Peers
Comparison fields: 5 of 59
- Rheumatology 291
- Molecular Biology 130
- Immunology 103
- Hematology 65
- Genetics 57
Countries citing papers authored by Liqing Ni
This map shows the geographic impact of Liqing Ni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liqing Ni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liqing Ni more than expected).
Fields of papers citing papers by Liqing Ni
This network shows the impact of papers produced by Liqing Ni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liqing Ni. The network helps show where Liqing Ni may publish in the future.
Co-authorship network of co-authors of Liqing Ni
This figure shows the co-authorship network connecting the top 25 collaborators of Liqing Ni. A scholar is included among the top collaborators of Liqing Ni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liqing Ni. Liqing Ni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 23 | |
| 2 | 31 | |
| 3 | 40 | |
| 4 | 124 | |
| 5 | Overexpression of osteopontin in rheumatoid synovial mononuclear cells is associated with joint inflammation, not with genetic polymorphism. | 31 |
| 6 | 118 | |
| 7 | Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial | 7 |
| 8 | Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial. | 29 |
| 9 | [Retrospective study of adverse events in patients with rheumatoid arthritis treated with second-line drugs]. | 7 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.